{"name":"Cue Biopharma","slug":"cue","ticker":"CUE","exchange":"NASDAQ","domain":"cuebiopharma.com","description":"Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pa","hq":"Boston, MA","founded":0,"employees":"29","ceo":"Daniel R. Passeri","sector":"Immuno-Oncology / Immunology","stockPrice":0.21,"stockChange":0.02,"stockChangePercent":10.53,"marketCap":"$20M","metrics":{"revenue":27466000,"revenueGrowth":1292.3,"grossMargin":-26.9,"rdSpend":37743000,"netIncome":-26602000,"cash":28229000,"dividendYield":0,"peRatio":-0.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Cue Biopharma reported its financial results for the fourth quarter and full year 2023, with a net loss of $24.6 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Cue Biopharma Announces Collaboration with Merck KGaA to Develop Immunotherapies for Cancer","summary":"Cue Biopharma announced a collaboration with Merck KGaA to develop immunotherapies for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPeDlqQ000SDlwNXJUQ0k2U2d5bjVrVVRyWTI2Z2pPcGNKM2hZSndPdFQxaHU4SVdKdXN2VThMbjFEb0tmRUFUYXZTUE9heElQU09XeWtIaU5XSnJmMEhNYzdwTTRPVnluclNUUHlON00wRndHYWw0VkJFWEIxblgxTzMxd1gxOHVUVU1yaUsta2lnbXd6alVTdGRocy1WNzZ6Rjg0eDJ1LTNDNmZuTWh1cFF2NA?oc=5","date":"2026-04-08","type":"pipeline","source":"The Pharma Letter","summary":"Boehringer pays Cue Biopharma $7.5M to progress lead autoimmune asset - The Pharma Letter","headline":"Boehringer pays Cue Biopharma $7.5M to progress lead autoimmune asset","sentiment":"neutral"},{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNUjk5cFFyQnR2UVJRRFJYalpDbUlVTnJIOGdabHh3QlBRQ0xtSkNFVTRhMGM1WTk0U2d2VVF3UzhSRnBLdTZrVkN1cjVrbTBYRjZ5OUtoX3VHV1NnblJwMEhoZEh6cXJCSzdOMFlCVUVqRUJHZVJDVldCVk5DZ0l4bXBsNXhKdzBUVlVRVHpHNTlldi1SSnB0M3lCU2VvNmc?oc=5","date":"2026-04-02","type":"pipeline","source":"Fierce Biotech","summary":"Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders - Fierce Biotech","headline":"Bayer radiology head takes top U.S. pharma spot—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOaWxVTzc4SmE2di1lMTgySlBabm41djJlcWdLYy1nYWpEb2tMek9xV2o4bWJ1MzhGdGI3WlY5b1ZJeG9USGRaZUI2ZnN3Yk9vam1sc1c2VTk3Z3Z5UHo0dng1NEFib0poVUlDcTJkZlVlejYxcFE1aVRjTHBsMXdQbVlYVHllTGh2eWowY2tGLTZJeVhpMlE3eFFheVNzZVozYy15VUM4eWQtOHNFVkxV?oc=5","date":"2026-03-27","type":"pipeline","source":"GlobeNewswire","summary":"Cue Biopharma Announces CEO Transition - GlobeNewswire","headline":"Cue Biopharma Announces CEO Transition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQZFB1SnZyVVZfUWtXRldSbkVIZkhrMjhtNzRzbHVjSVc1ejMtc2VtZGoxeVh1RHU0elFmTjBPZEdsSnVTVk0yX2pFdjE2anBqLUhUUjRaT0JmeXZrR2hKX0NNTjFWZnF4aWkwZkNTaXA3aklMajJ5LVFOYmQxNS1lXzg4aHBfNzB0?oc=5","date":"2026-03-27","type":"pipeline","source":"Stock Titan","summary":"Cue Biopharma swaps CEOs as Lucinda Warren takes interim post - Stock Titan","headline":"Cue Biopharma swaps CEOs as Lucinda Warren takes interim post","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPaHdoX1BFcExZOUZaZjVBZmE5a194eHJnMlRYQkU3UkZQM01zNzJfVTBXQmFKOHgwLV9lNU9sdXJLT0piUno5MUJmYXNZQm9rOEIxRHNtem0xTTY0aW0wSHg1MXFieDhCSml0SGx5d0pyakRYNXd5d2prUDcydF9GNzZBdVpHRVlzUENIWlJVTjB3QXZmcHQw?oc=5","date":"2026-02-20","type":"pipeline","source":"bioxconomy.com","summary":"Biotech companies appoint new chief finance heads - bioxconomy.com","headline":"Biotech companies appoint new chief finance heads","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNHRNcUVVZlNvV21UWEdmTXRVenhMbEg5UU8yZ1hwWTM3ZjFTQi1sUEV2b1FNZzFUMVFrNjU1Z0xleUpsUVJpOTcwZWp2Y0M4d01XRzlPdjQyM1ZMMFBwMUYtQ1FFRG0tWWIwV2FpellHR0l1M0ZPMnlHNTVhaVB1RmRKSXptallncDZqN213bTVDX3VZdUVGWlFCTzhVOVdCbHFDNlRPOGkzd3lBd3BCdlBWbllsUWJa?oc=5","date":"2026-02-12","type":"pipeline","source":"Stock Titan","summary":"30-year pharma veteran Lucinda Warren to oversee finances at Cue Biopharma - Stock Titan","headline":"30-year pharma veteran Lucinda Warren to oversee finances at Cue Biopharma","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBLbGlaM1o5dVpLa093ajNtMDR1VFpOTHhtYUcxN1NBb2t1R0o0ZkRZdkhvX0RDZzVNYUs2LVh2QUpXVENHQWZ0NkxEczBfSXd3QW1j?oc=5","date":"2026-01-27","type":"pipeline","source":"firstwordpharma.com","summary":"Boehringer inks €1.05B pact with Simcere for preclinical IBD bispecific - firstwordpharma.com","headline":"Boehringer inks €1.05B pact with Simcere for preclinical IBD bispecific","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONGRscGV6TUw0N0NqbEg2d3o2LTM2clJUUTdfcVRHTVVUTEg0YVQtSnZEWUZwY2NFOTN3UDZHSV83eExGYlFMdUdhVmFteUNUWUtQSWFzdG1EVTg5eThzSFh6SGFLTmlIdGU3ZEtCYjlIaHFFNXBHTmJTTlRRQ1dKSg?oc=5","date":"2025-12-03","type":"deal","source":"Labiotech.eu","summary":"Boehringer Ingelheim's pipeline activity: A busy year of dealmaking for the German pharma in 2025 - Labiotech.eu","headline":"Boehringer Ingelheim's pipeline activity: A busy year of dealmaking for the German pharma in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOM2dCUHVlYjB1UnhkV0h5aVhYWkN3d3VTS2NzTFg4OFFWZEFROFNMWmZBSm1kRnRpZ2VrNXRZY3UwdlZmWGJNdzlyRVU0cWtNRnM0YmJtdkpZQmptZXZPeUVNN3E1aVE1SVlnYVZweWh4eDc5dVhyOVZRQnRuSWYtVDN0bzduRkw3ZXh4ck13Z0pPTUZjTy1PeG9vOEhiRmp5aGV0NHlmdjlCZw?oc=5","date":"2025-10-15","type":"deal","source":"BioSpace","summary":"Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal - BioSpace","headline":"Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Immuno-Oncology","Immunology"],"financials":{"source":"sec_edgar","revenue":27466000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":27466000,"period":"2025-12-31"},{"value":9287000,"period":"2024-12-31"},{"value":9287000,"period":"2024-12-31"},{"value":5490000,"period":"2023-12-31"},{"value":5490000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37743000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26602000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":42212000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.21,"previousClose":0.19,"fiftyTwoWeekHigh":1.03,"fiftyTwoWeekLow":0.17,"fiftyTwoWeekRange":"0.166 - 1.03","fiftyDayAverage":0.29,"twoHundredDayAverage":0.57,"beta":1.58,"enterpriseValue":-5652239,"forwardPE":-0.4,"priceToBook":0.76,"priceToSales":0.74,"enterpriseToRevenue":-0.21,"enterpriseToEbitda":0.22,"pegRatio":0,"ebitda":-25563000,"ebitdaMargin":-93.1,"freeCashflow":-9951750,"operatingCashflow":-21687000,"totalDebt":4197000,"debtToEquity":15.9,"currentRatio":2.74,"returnOnAssets":-44.6,"returnOnEquity":-121.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":4,"targetHighPrice":4,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.6,"institutionHeldPercent":22.3,"sharesOutstanding":97660791,"floatShares":97070920,"sharesShort":2272639,"shortRatio":3.41,"shortPercentOfFloat":2.3,"epsTrailing":-0.28,"epsForward":-0.48,"revenuePerShare":0.29,"bookValue":0.27,"officers":[{"age":55,"name":"Ms. Lucinda  Warren","title":"Interim CEO, Interim President,Principal Fin & Accounting Off., Chief Financial & Business Off."},{"age":67,"name":"Mr. Colin G. Sandercock J.D., MSE","title":"Senior VP, General Counsel & Secretary"},{"age":49,"name":"Dr. Ronald D. Seidel III, Ph.D.","title":"Co-Founder"},{"age":52,"name":"Dr. Rodolfo Jose Chaparro Ph.D.","title":"Co-Founder"},{"age":64,"name":"Dr. Steven C. Almo Ph.D.","title":"Co-Founder and Chairman of Scientific & Clinical Advisory Board"},{"age":75,"name":"Dr. Daniel G. Baker M.D., Ph.D.","title":"Interim Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.cuebiopharma.com","phone":"617 949 2680"}}